Roche (RHHBY) plans to invest up to $550M in its Diagnostics site in Indianapolis by 2030. The site will become a major hub for the manufacturing of Roche’s continuous glucose monitoring systems. With more than 38 million Americans living with diabetes, access to effective disease management solutions is crucial. To address this growing need, Roche is investing in a new CGM manufacturing facility in Indianapolis. CGM technologies offer essential support for daily diabetes management, and this investment will help advance Roche’s mission to improve patient care through innovation. The expansion is expected to generate hundreds of highly-skilled manufacturing jobs and thousands of construction jobs, providing a significant boost to Indiana’s economy. It will also enhance domestic production capabilities and reduce dependency on imports.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche, Genentech announce new North Carolina manufacturing facility
- Trump to sign executive order aimed at lowering drug prices
- Pharma imports to U.S. surged in March ahead of tariffs, Reuters says
- FDA announces expanded use of unannounced inspections at foreign facilities
- Trump to sign order streamlining U.S. drug manufacturing regulations, WaPo says